Neurology Collaboration Lead candidate AV078 is a CNS-penetrant mTORC1 inhibitor in Phase 2 for tuberous sclerosis complex related refractory epilepsy, presenting a clear licensing or co-development opportunity with neurology-focused partners to accelerate CNS trial timelines and access orphan patient populations.

Pipeline Expansion Aeovian's proprietary library includes potent and selective mTORC1 and CD38 inhibitors, enabling a broad potential for additional rare and age-related disease indications; explore targeted co-development or in-licensing discussions to expand the commercial footprint.

Funding Momentum Recent Series B funding of 55 million led by CTI Life Sciences Fund and Luma Group, along with involvement from the TSC Alliance Endowment Fund, signals credible validation and potential favorable upfronts and milestones in partnership deals.

Strategic Leadership Board additions from pharma veterans can accelerate deal execution; leverage these relationships to structure collaboration, licensing, or co-development agreements with favorable terms.

Ecosystem Access Engagement with patient advocacy and philanthropic investors like the TSC Alliance suggests faster trial access and potential payer discussions; align BD outreach with patient networks and clinical sites to facilitate partnerships.